Kamada (NASDAQ:KMDA) Downgraded by StockNews.com to Buy

Kamada (NASDAQ:KMDA) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report released on Tuesday.

Several other equities research analysts also recently weighed in on the company. Benchmark began coverage on Kamada in a research report on Friday. They set a “buy” rating and a $15.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Kamada in a report on Thursday, March 6th.

Kamada Trading Down 0.3 %

Shares of KMDA stock traded down $0.02 during trading hours on Tuesday, hitting $7.08. The company’s stock had a trading volume of 61,393 shares, compared to its average volume of 78,691. The company has a 50 day moving average of $7.19 and a 200 day moving average of $6.28. Kamada has a 12-month low of $4.74 and a 12-month high of $9.16. The stock has a market cap of $406.96 million, a PE ratio of 25.29, a price-to-earnings-growth ratio of 0.97 and a beta of 0.97.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Public Employees Retirement System of Ohio acquired a new stake in shares of Kamada during the 3rd quarter valued at about $77,000. JPMorgan Chase & Co. purchased a new position in Kamada during the fourth quarter worth approximately $67,000. Geode Capital Management LLC grew its holdings in Kamada by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after purchasing an additional 1,549 shares during the period. NewEdge Advisors LLC increased its position in shares of Kamada by 54.2% in the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 8,260 shares in the last quarter. Finally, Aristides Capital LLC raised its stake in shares of Kamada by 12.1% during the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company’s stock worth $387,000 after buying an additional 6,850 shares during the period. Institutional investors and hedge funds own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.